NASDAQ:EQ

Equillium (EQ) Stock Price, News & Analysis

Equillium logo
$1.06 -0.06 (-5.36%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.05 -0.01 (-1.32%)
As of 11/20/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Equillium Stock (NASDAQ:EQ)

Advanced

Key Stats

Today's Range
$1.06
▼
$1.17
50-Day Range
$1.06
▼
$2.10
52-Week Range
$0.81
▼
$3.54
Volume
567,888 shs
Average Volume
341,783 shs
Market Capitalization
$87.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13
Consensus Rating
Moderate Buy

Company Overview

Equillium is a biotechnology company focused on developing medicines that target immune pathways involved in autoimmune and inflammatory diseases. Its research has centered on treatments for conditions with significant unmet medical needs.

The company’s leading program has been itolizumab, a monoclonal antibody that targets CD6, an immune-cell protein. Equillium obtained development and commercialization rights to itolizumab from India-based Biocon for several markets, including the United States, Canada, Australia and New Zealand. Biocon has separately marketed the medicine in India.

Equillium has also pursued other immunology programs, including investigational therapies designed to modulate cytokine signaling. These programs and product candidates are in development and are not necessarily approved or available for sale.

AI Generated. May Contain Errors.

Equillium Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

EQ MarketRank™: 
2.20227240847 of 5 stars

Equillium scored higher than 44% of companies evaluated by MarketBeat, and ranked 555th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Equillium has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Equillium has a consensus price target of $7.13, representing about 572.2% upside from its current price of $1.06.

  • Amount of Analyst Coverage

    Equillium has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Equillium's stock forecast and price target.
  • Earnings Growth

    Earnings for Equillium are expected to decrease in the coming year, from ($0.19) to ($0.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Equillium is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Equillium is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Equillium has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.37% of the float of Equillium has been sold short.
  • Short Interest Ratio / Days to Cover

    Equillium has a short interest ratio ("days to cover") of 9.52.
  • Change versus previous month

    Short interest in Equillium has recently increased by 4.74%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Equillium does not currently pay a dividend.

  • Dividend Growth

    Equillium does not have a long track record of dividend growth.

  • News Sentiment

    Equillium has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Equillium this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Equillium insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.84% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    27.05% of the stock of Equillium is held by institutions.

  • Read more about Equillium's insider trading history.
Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EQ Stock News Headlines

Reviewing Oncobiologics (NASDAQ:OTLK) and Equillium (NASDAQ:EQ)
Equillium Q3 Loss Widens On Higher R&D Expenses
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
See More Headlines

EQ Stock Analysis - Frequently Asked Questions

Equillium's stock was trading at $1.55 at the start of the year. Since then, EQ shares have decreased by 31.6% and is now trading at $1.06.

Equillium, Inc. (NASDAQ:EQ) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01.

Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,670,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

Top institutional investors of Equillium include Aberdeen Group plc (7.03%), RA Capital Management L.P. (3.66%), Marshall Wace LLP (1.18%) and State Street Corp (0.31%). Insiders that own company stock include Stephen Connelly, Penny Tom and Christine Zedelmayer.
View institutional ownership trends
.

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include Inovio Pharmaceuticals (INO), AMC Entertainment (AMC), NIO (NIO), Pfizer (PFE), Block (XYZ), Micron Technology (MU) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/12/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EQ
CIK
1746466
Fax
N/A
Employees
14
Year Founded
2017

Price Target and Rating

High Price Target
$12.00
Low Price Target
$4.00
Potential Upside/Downside
+572.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.40 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-37.33%
Return on Assets
-35.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.49
Quick Ratio
19.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.64 per share
Price / Book
1.66

Miscellaneous

Outstanding Shares
82,325,000
Free Float
67,638,000
Market Cap
$87.26 million
Optionable
Optionable
Beta
2.08

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:EQ) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners